Follow
ENMING XING
Title
Cited by
Cited by
Year
Rationally designed ACE2-derived peptides inhibit SARS-CoV-2
RC Larue, E Xing, AD Kenney, Y Zhang, JA Tuazon, J Li, JS Yount, PK Li, ...
Bioconjugate chemistry 32 (1), 215-223, 2020
802020
Cycloruthenated Self‐Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers
J Li, L Zeng, Z Wang, H Chen, S Fang, J Wang, CY Cai, E Xing, X Liao, ...
Advanced Materials 34 (1), 2100245, 2022
312022
BET bromodomain inhibitors: novel design strategies and therapeutic applications
KKW To, E Xing, RC Larue, PK Li
Molecules 28 (7), 3043, 2023
172023
Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design
R Sheng, L Yang, Y Zhang, E Xing, R Shi, X Wen, H Wang, H Sun
Bioorganic & Medicinal Chemistry Letters 28 (15), 2599-2604, 2018
132018
Constitutively active androgen receptor in Hepatocellular Carcinoma
EJ Montgomery, E Xing, MJ Campbell, PK Li, JS Blachly, A Tsung, ...
International journal of molecular sciences 23 (22), 13768, 2022
122022
Size-dependent effect of Cu2O nanocubes in electrochemical and photocatalytic properties
Y Tang, Y Xu, C Qi, X Li, E Xing, F Wang, Z Kan, C Wang, J Tang, ...
Journal of Nanoscience and Nanotechnology 18 (12), 8282-8288, 2018
112018
Development of murine leukemia virus integrase-derived peptides that bind Brd4 extra-terminal domain as candidates for suppression of acute myeloid leukemia
E Xing, N Surendranathan, X Kong, N Cyberski, JD Garcia, X Cheng, ...
ACS Pharmacology & Translational Science 4 (5), 1628-1638, 2021
52021
Mechanistic insights into the allosteric inhibition of androgen receptors by binding function 3 antagonists from an integrated molecular modeling study
X Kong, E Xing, T Zhuang, PK Li, X Cheng
Journal of Chemical Information and Modeling 61 (7), 3477-3494, 2021
52021
Computational modeling studies reveal the origin of the binding preference of 3‐(3, 4‐di hydroisoquinolin‐2 (1H)‐ylsulfonyl) benzoic acids for AKR1C3 over its isoforms
X Kong, E Xing, S Wu, T Zhuang, PK Li, C Li, X Cheng
Protein Science 31 (12), e4499, 2022
32022
BET PROTEIN INHIBITORS AND USE THEREOF
AC Gao, P Li, M Foster, R Larue, CM Armstrong, W Lou, S Ning, E Xing
US Patent App. 18/548,844, 2024
2024
Novel dual inhibitors of AR/AR variants and AKR1C3: Preclinical activities for advanced prostate cancer therapy.
A Gao, S Ning, C Armstrong, E Xing, W Lou, PK Li, CP Evans
Journal of Clinical Oncology 42 (4_suppl), 169-169, 2024
2024
SAT021 Development Of Niclosamide Analogs For Treatment Of Androgen Receptor Positive Hepatocellular Carcinoma
E Jordan Montgomery, E Xing, A Dauki, H Radomska, S Kiyota Kulp, ...
Journal of the Endocrine Society 7 (Supplement_1), bvad114. 1759, 2023
2023
Design, synthesis, and screening of niclosamide analogs as androgen receptor degraders for hepatocellular carcinoma
J Cheng, E Xing, S Mohammed, E Montgomery, L Granchie, C Coss, ...
Cancer Research 83 (7_Supplement), 3106-3106, 2023
2023
Dual androgen receptor/akr1c3 inhibitors
AC Gao, PK Li, E Xing, X Cheng, X Kong, W Lou
US Patent App. 17/745,621, 2023
2023
Design, synthesis and study of small molecules with both AR degradation and AKR1C3 inhibitory activities
E Xing, X Kong, W Lou, R Shi, X Cheng, AC Gao, PK Li
Cancer Research 80 (16_Supplement), 5681-5681, 2020
2020
The system can't perform the operation now. Try again later.
Articles 1–15